Quick Answer
Zivo Bioscience, Inc. reported Cash and Equivalents of $1.80 million for fiscal year 2022.
Zivo Bioscience, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $1.80M | -79.8% |
| 2021 | $8.90M | +6357.1% |
| 2020 | $137.9K | -60.2% |
| 2019 | $346.1K | -11.0% |
| 2018 | $388.9K | +22.6% |
| 2017 | $317.1K | -37.4% |
| 2016 | $507.0K | +2956.2% |
| 2015 | $16.6K | +1099.5% |
| 2014 | $1.4K | -99.7% |
| 2013 | $493.1K | +945.9% |
| 2012 | $47.1K | -79.1% |
| 2011 | $225.7K | +1346.5% |
| 2010 | $15.6K | — |
| 2009 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2022 | $5.08M | -53.4% | -23.0% |
| March 31, 2022 | $6.60M | +2745.2% | -25.9% |
| December 31, 2021 | $8.90M | +6357.1% | -17.6% |
| September 30, 2021 | $10.80M | +19412.0% | -0.9% |
| June 30, 2021 | $10.90M | +9072.5% | +4601.0% |
| March 31, 2021 | $231.9K | +2209.4% | +68.2% |
| December 31, 2020 | $137.9K | -60.2% | +149.0% |
| September 30, 2020 | $55.4K | +258.9% | -53.4% |
- Zivo Bioscience, Inc. showed a decrease of -79.8% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Zivo Bioscience, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 14, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: